Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

被引:3
|
作者
Adesoye, Taiwo [1 ]
Tripathy, Debasish [2 ]
Hunt, Kelly K. [1 ]
Keyomarsi, Khandan [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
关键词
STAT3; cancer; therapeutics; EPIDERMAL-GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; DNA-BINDING ACTIVITY; HUMAN BREAST-CANCER; TRANSCRIPTION; SMALL-MOLECULE; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; DECOY OLIGONUCLEOTIDE; DRUG-RESISTANCE;
D O I
10.3390/cancers16030492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Signal Transducer and Activator of Transcription 3 (STAT3) is involved in many normal cellular processes that are tightly regulated. However, aberrant activation of STAT3 has been implicated in cancer development, recurrence, and metastasis in addition to development of resistance to therapy. Significant progress has been made in targeting STAT3 directly and indirectly through the development of novel therapeutic agents, although some drugs remain in the early phases of development, demonstrating promising potential for future clinical applications. There are several STAT3 inhibitors in clinical trials as monotherapy, and in combination with chemotherapeutic agents and biomarker analysis from these trials, will be critical to inform which patients will benefit from prolonged STAT3 inhibition.Abstract Signal Transducer and Activator of Transcription 3 (STAT3) plays a significant role in diverse physiologic processes, including cell proliferation, differentiation, angiogenesis, and survival. STAT3 activation via phosphorylation of tyrosine and serine residues is a complex and tightly regulated process initiated by upstream signaling pathways with ligand binding to receptor and non-receptor-linked kinases. Through downstream deregulation of target genes, aberrations in STAT3 activation are implicated in tumorigenesis, metastasis, and recurrence in multiple cancers. While there have been extensive efforts to develop direct and indirect STAT3 inhibitors using novel drugs as a therapeutic strategy, direct clinical application remains in evolution. In this review, we outline the mechanisms of STAT3 activation, the resulting downstream effects in physiologic and malignant settings, and therapeutic strategies for targeting STAT3. We also summarize the pre-clinical and clinical evidence of novel drug therapies targeting STAT3 and discuss the challenges of establishing their therapeutic efficacy in the current clinical landscape.
引用
收藏
页数:30
相关论文
共 50 条
  • [21] The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
    Bishop, Jennifer L.
    Thaper, Daksh
    Zoubeidi, Amina
    [J]. CANCERS, 2014, 6 (02) : 829 - 859
  • [22] A Novel STAT3 mutation Associated with Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling.
    Hu, Guangzhen
    Witzig, Thomas E.
    Gupta, Mamta
    [J]. BLOOD, 2012, 120 (21)
  • [23] Novel small molecule inhibitors of STAT3 in cancer
    Bhasin, Deepak
    Chettiar, Somsundaram
    Li, Chenglong
    Lin, Jiayuh
    Li, Pui Kai
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [24] Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting STAT3 and Blocking Phosphorylation and Activation of STAT3
    Yu, Xiaokui
    He, Li
    Cao, Peng
    Yu, Qiang
    [J]. PLOS ONE, 2015, 10 (05):
  • [25] INHIBITION OF STAT3 SIGNALING AS A NOVEL WAY TO ANTI-PSORIASIS
    Takaishi, Mikiro
    Miyoshi, Ken
    Nakajima, Kimiko
    Sano, Shigetoshi
    [J]. JOURNAL OF GENE MEDICINE, 2010, 12 (12): : 1068 - 1068
  • [26] ECHS1 interacts with STAT3 and negatively regulates STAT3 signaling
    Chang, Yan
    Wang, Shao-Xin
    Wang, Yu-Bo
    Zhou, Jie
    Li, Wei-Hua
    Wang, Na
    Fang, Di-Feng
    Li, Hui-Yan
    Li, Ai-Ling
    Zhang, Xue-Min
    Zhang, Wei-Na
    [J]. FEBS LETTERS, 2013, 587 (06) : 607 - 613
  • [27] Transcriptional Suppression of STAT3 by TGF-β Signaling in Hepatocellular Cancer
    Lin, Ling
    Yao, Zhixing
    Thenappan, Arun
    Jogunoori, Wilma S.
    Mishra, Lopa
    He, Aiwu R.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S249 - S249
  • [28] Stat3 Signaling in Human Breast Cancer Stem Cells.
    Wei, W.
    Zhang, M.
    Tweardy, D.
    Rosen, J.
    Lewis, M.
    [J]. CANCER RESEARCH, 2011, 71
  • [29] The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
    Tan, Fiona H.
    Putoczki, Tracy L.
    Stylli, Stanley S.
    Luwor, Rodney B.
    [J]. CURRENT DRUG TARGETS, 2014, 15 (14) : 1341 - 1353
  • [30] HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression
    Junk, Damian J.
    Bryson, Benjamin L.
    Jackson, Mark W.
    [J]. CANCERS, 2014, 6 (02) : 741 - 755